

CLAIMS

1. A T cell which comprises a chimeric antigen receptor (CAR) and a truncated protein which comprises:
 - (i) a PTPN6 SH2 domain which binds a phosphorylated immunoreceptor tyrosine-based inhibition motif (ITIM) but lacks a PTPN6 phosphatase domain; or
 - (ii) a SHP-2 SH2 domain which binds a phosphorylated ITIM but lacks a SHP-2 phosphatase domain.
2. A nucleic acid construct, which comprises:
 - a first nucleic acid sequence encoding a chimeric antigen receptor; and
 - a second nucleic acid sequence encoding a truncated protein as defined in Claim 1.
3. A vector which comprises a nucleic acid construct according to Claim 2.
4. A vector according to Claim 3, which is a retroviral or lentiviral vector.
5. A pharmaceutical composition comprising a plurality of T cells according to Claim 1.
6. A pharmaceutical composition according to Claim 5 for use in treating a disease.
7. A pharmaceutical composition for use according to Claim 6, in which:
 - (i) a cell containing sample is isolated from a subject;
 - (ii) the cells are transduced or transfected with a nucleic acid construct according to Claim 2 or a vector according to Claim 3 or 4; and
 - (iii) the cells from (ii) are to be administered to the subject.
8. Use of a pharmaceutical composition according to Claim 5 in the manufacture of a medicament for the treatment of cancer.
9. A pharmaceutical composition for use according to Claim 6 or 7, in which the disease is cancer.
10. A method for making a cell according to Claim 1, which comprises the step of introducing: a nucleic acid construct according to Claim 2 or a vector according to Claim 3 or 4, into the cell *ex vivo*.

11. A method according to Claim 10, in which the cell is from a sample isolated from a subject.